ASCO 2019 day five
Exclusive live coverage from day five of the American Society of Clinical Oncology’s annual meeting in Chicago.
• To view all of our coverage from the preeminent cancer event, produced in association with Kantar Health, as well as additional content, visit the Spotlight on ASCO 2019 and the future of oncology
On the agenda for Tuesday:
- An oral presentation will discuss results of a phase 2 trial of Ipsen/Exelixis’ cabozantinib vs. chemotherapy, based on data from the phase 2 Alliance A091201 study in metastatic and primary uveal melanoma.
View the live coverage from day five at ASCO 2019 below (the live blog may take a few seconds to load):